B-intervention	0	10	Ribociclib
I-intervention	11	15	plus
I-intervention	16	25	letrozole
O	26	28	in
O	29	34	early
O	35	41	breast
O	42	48	cancer
O	48	49	:
O	50	51	A
O	52	63	presurgical
O	63	64	,
O	65	71	window
O	71	72	-
O	72	74	of
O	74	75	-
O	75	86	opportunity
O	87	92	study
O	92	93	.

O	94	100	Cyclin
O	101	102	D
O	102	103	-
O	103	109	cyclin
O	109	110	-
O	110	119	dependent
O	120	126	kinase
O	127	128	(
O	128	131	CDK
O	131	132	)
O	133	134	4
O	134	135	/
O	135	136	6
O	136	137	-
O	137	146	inhibitor
O	147	149	of
O	150	154	CDK4
O	154	155	/
O	155	156	6
O	156	157	-
O	157	171	retinoblastoma
O	172	173	(
O	173	175	Rb
O	175	176	)
O	177	184	pathway
O	185	200	hyperactivation
O	201	203	is
O	204	214	associated
O	215	219	with
O	220	227	hormone
O	228	236	receptor
O	236	237	-
O	237	245	positive
O	246	247	(
O	247	249	HR
O	249	250	+
O	250	251	)
O	252	258	breast
O	259	265	cancer
O	266	267	(
O	267	269	BC
O	269	270	)
O	270	271	.

O	272	276	This
O	277	282	study
O	283	291	assessed
O	292	295	the
O	296	306	biological
O	307	315	activity
O	316	318	of
O	319	329	ribociclib
O	330	331	(
O	331	337	LEE011
O	337	338	;
O	339	343	CDK4
O	343	344	/
O	344	345	6
O	346	355	inhibitor
O	355	356	)
O	357	361	plus
O	362	371	letrozole
O	372	380	compared
O	381	385	with
O	386	392	single
O	392	393	-
O	393	398	agent
O	399	408	letrozole
O	409	411	in
O	412	415	the
O	416	427	presurgical
O	428	435	setting
O	435	436	.

O	437	451	Postmenopausal
O	452	457	women
O	458	459	(
O	459	460	N
O	461	462	=
B-total-participants	463	465	14
O	465	466	)
O	467	471	with
O	472	482	resectable
O	482	483	,
O	484	486	HR
O	486	487	+
O	487	488	,
O	489	494	human
O	495	504	epidermal
O	505	511	growth
O	512	518	factor
O	519	527	receptor
O	528	529	2
O	529	530	-
O	530	538	negative
O	539	540	(
O	540	544	HER2
O	544	545	-
O	545	546	)
O	547	552	early
O	553	555	BC
O	556	560	were
O	561	571	randomized
O	572	573	1
O	573	574	:
O	574	575	1
O	575	576	:
O	576	577	1
O	578	580	to
O	581	588	receive
O	589	590	2
O	590	591	.
O	591	592	5
O	593	595	mg
O	595	596	/
O	596	599	day
B-control	600	609	letrozole
I-control	610	615	alone
O	616	617	(
O	617	620	Arm
O	621	622	1
O	622	623	)
O	623	624	,
O	625	627	or
O	628	632	with
O	633	636	400
O	637	639	or
O	640	643	600
O	644	646	mg
O	646	647	/
O	647	650	day
O	651	661	ribociclib
O	662	663	(
O	663	666	Arm
O	667	668	2
O	669	671	or
O	672	673	3
O	673	674	)
O	674	675	.

O	676	687	Circulating
O	688	693	tumor
O	694	697	DNA
O	698	701	and
O	702	707	tumor
O	708	716	biopsies
O	717	721	were
O	722	731	collected
O	732	734	at
O	735	743	baseline
O	744	747	and
O	747	748	,
O	749	758	following
O	759	761	14
O	762	766	days
O	767	769	of
O	770	779	treatment
O	779	780	,
O	781	786	prior
O	787	789	to
O	790	792	or
O	793	799	during
O	800	807	surgery
O	807	808	.

O	809	812	The
O	813	820	primary
O	821	830	objective
O	831	834	was
O	835	837	to
O	838	844	assess
B-outcome-Measure	845	862	antiproliferative
I-outcome-Measure	863	871	response
I-outcome-Measure	872	875	per
I-outcome-Measure	876	880	Ki67
I-outcome-Measure	881	887	levels
O	888	890	in
O	891	895	Arms
O	896	897	2
O	898	901	and
O	902	903	3
O	904	912	compared
O	913	917	with
O	918	921	Arm
O	922	923	1
O	923	924	.

O	925	935	Additional
O	936	947	assessments
O	948	956	included
B-outcome-Measure	957	963	safety
O	963	964	,
B-outcome-Measure	965	981	pharmacokinetics
O	981	982	,
O	983	986	and
B-outcome-Measure	987	994	genetic
I-outcome-Measure	995	1004	profiling
O	1004	1005	.

O	1006	1010	Mean
O	1011	1020	decreases
O	1021	1023	in
O	1024	1027	the
B-outcome	1028	1032	Ki67
I-outcome	1032	1033	-
I-outcome	1033	1041	positive
I-outcome	1042	1046	cell
I-outcome	1047	1055	fraction
O	1056	1060	from
O	1061	1069	baseline
O	1070	1074	were
O	1074	1075	:
O	1076	1079	Arm
O	1080	1081	1
B-cv-cont-mean	1082	1084	69
I-cv-cont-mean	1084	1085	%
O	1086	1087	(
O	1087	1092	range
O	1093	1095	38
O	1095	1096	-
O	1096	1099	100
O	1099	1100	%
O	1100	1101	;
O	1102	1103	n
O	1104	1105	=
O	1106	1107	2
O	1107	1108	)
O	1108	1109	,
O	1110	1113	Arm
O	1114	1115	2
B-iv-cont-mean	1116	1118	96
I-iv-cont-mean	1118	1119	%
O	1120	1121	(
O	1121	1126	range
O	1127	1129	78
O	1129	1130	-
O	1130	1133	100
O	1133	1134	%
O	1134	1135	;
O	1136	1137	n
O	1138	1139	=
O	1140	1141	6
O	1141	1142	)
O	1142	1143	,
O	1144	1147	Arm
O	1148	1149	3
B-iv-cont-mean	1150	1152	92
I-iv-cont-mean	1152	1153	%
O	1154	1155	(
O	1155	1160	range
O	1161	1163	75
O	1163	1164	-
O	1164	1167	100
O	1167	1168	%
O	1168	1169	;
O	1170	1171	n
O	1172	1173	=
O	1174	1175	3
O	1175	1176	)
O	1176	1177	.

O	1178	1187	Decreased
O	1188	1202	phosphorylated
O	1203	1205	Rb
O	1206	1212	levels
O	1213	1216	and
O	1217	1221	CDK4
O	1221	1222	,
O	1223	1227	CDK6
O	1227	1228	,
O	1229	1234	CCND2
O	1234	1235	,
O	1236	1241	CCND3
O	1241	1242	,
O	1243	1246	and
O	1247	1252	CCNE1
O	1253	1257	gene
O	1258	1268	expression
O	1269	1273	were
O	1274	1282	observed
O	1283	1292	following
O	1293	1303	ribociclib
O	1304	1313	treatment
O	1313	1314	.

O	1315	1325	Ribociclib
O	1326	1329	and
O	1330	1339	letrozole
O	1340	1355	pharmacokinetic
O	1356	1366	parameters
O	1367	1371	were
O	1372	1382	consistent
O	1383	1387	with
O	1388	1394	single
O	1394	1395	-
O	1395	1400	agent
O	1401	1405	data
O	1405	1406	.

O	1407	1410	The
O	1411	1421	ribociclib
O	1422	1426	plus
O	1427	1436	letrozole
O	1437	1448	combination
O	1449	1452	was
B-outcome	1453	1457	well
I-outcome	1458	1467	tolerated
O	1467	1468	,
O	1469	1473	with
O	1474	1476	no
B-outcome	1477	1482	Grade
I-outcome	1483	1484	3
I-outcome	1484	1485	/
I-outcome	1485	1486	4
I-outcome	1487	1494	adverse
I-outcome	1495	1501	events
O	1502	1506	over
O	1507	1510	the
O	1511	1520	treatment
O	1520	1521	.

O	1522	1525	The
O	1526	1533	results
O	1534	1541	suggest
O	1542	1549	absence
O	1550	1552	of
O	1553	1554	a
O	1555	1559	drug
O	1559	1560	-
O	1560	1564	drug
O	1565	1576	interaction
O	1577	1584	between
O	1585	1595	ribociclib
O	1596	1599	and
O	1600	1609	letrozole
O	1610	1613	and
O	1614	1622	indicate
O	1623	1633	ribociclib
O	1634	1638	plus
O	1639	1648	letrozole
O	1649	1652	may
O	1653	1659	reduce
O	1660	1664	Ki67
O	1665	1675	expression
O	1676	1678	in
O	1679	1681	HR
O	1681	1682	+
O	1682	1683	,
O	1684	1688	HER2
O	1688	1689	-
O	1690	1692	BC
O	1693	1694	(
O	1694	1705	NCT01919229
O	1705	1706	)
O	1706	1707	.
